TOMATO XYLOGLUCAN ENDO-TRANSGLYCOSYLASE

Abstract: Disclosed is a polypeptide having xyloglucan endo-transglycosylase (XET) activity, comprising substantially residues 21-289 of the amino acid sequence shown in Figure 1 (Seq ID No. 2) or functional equivalents thereof, together with nucleotide sequences encoding the same and various uses thereof.

Description: TOMATO XYLOGLUCAN ENDO-TRANSGLYCOSYLASE Field of the Invention This invention relates to nucleotide sequences encoding a plant enzyme, vectors containing said nucleotide sequences, hosts containing said nucleotide sequences, amino acid sequences encoded by said nucleotide sequences, recombinant DNA methods of producing the enzyme, and a method of altering the properties of a plant. Background of the Invention Fruit and vegetable cell walls are largely polysaccharide, the major components being pectin, cellulose and xyloglucan (Selvendran & Robertson, IFR Report 1989). Numerous cell wall models have been proposed which attempt to incorporate the essential properties of strength and flexibility (e.g. Albersheim, 1975 Sci. Am. 232, 81-95; Albershei , 1976 "The primary cell wall", Plant Biochemistry, 3rd Edition, Academic Press; and Hayashi, 1989, Ann. Rev. Plant Physiol. & Plant Mol. Biol. 40, 139-168). Xyloglucans are 1 ,4-/3-glucans that are extensively substituted with α-l,6-xylosyl side chains, some of which are 1,2 3-galactosylated. They are found in large amounts in the primary cell walls of dicots but also in certain seeds, where they serve different roles. Primary cell wall xyloglucan is tightly hydrogen bonded to cellulose microfibrils and requires concentrated alkali or strong swelling agents to release it. Xyloglucan is thought to form cross-bridges between cellulose microfibrils, the cellulose/xyloglucan network forming the major load-bearing/elastic network of the wall. DCB mutated suspension culture cells (cell walls lacking cellulose) release xyloglucan into their media, suggesting that xyloglucan is normally tightly bound to cellulose. Hydrolysis of primary cell wall xyloglucan has been demonstrated in segments of dark grown squash hypocotyls, during IAA induced growth (Wakabayashi et al., 1991 Plant Physiol. 95, 1070-1076). Endohydrolysis of wall xyloglucan is thought to contribute to the wall loosening which accompanies cell expansion (Hayashi, cited previously). The average molecular weight of xyloglucan has also been shown to decrease during tomato fruit ripening and this may contribute to the tissue softening which accompanies the ripening process (Huber, 1983 J. Amer. Soc. Hort. Sci. 108, 405-409). Certain seeds, e.g. nasmrtium, contain up to 30% by weight of xyloglucan, stored in thickened cotyledonary cell walls, which serves as a reserve polysaccharide and is rapidly depolymerised during germination. An endo 1,4 3-D glucanase which specifically acts on xyloglucan (i.e. a xyloglucanase) has been isolated and purified to apparent homogeneity from germinating nasturtium (Tropaeolwn majus L.) seeds (Edwards et al. , 1986 J. Biol. Chem. 26_1, 9494). The purified xyloglucanase gives a single polypeptide band on SDS polyacrylamide gel electrophoresis, (apparent molecular weight, 29-3 lkDa) and isoelectric focusing (isoelectric point, 5.0). The enzyme displays an absolute specificity for xyloglucan and an endo mode of action, as determined by end product analysis following hydrolysis of tamarind seed xyloglucan (Wakabayashi et al. , cited above). Although the natural substrate of the enzyme is nasturtium cotyledonary reserve xyloglucan, it has also been shown to hydrolyse primary cell wall xyloglucans in vitro (Edwards et al. , cited previously). At high substrate concentrations, xyloglucan endo-transglycosylase (XET) activity has been demonstrated (Fanutti et al., 1993 The Plant Journal 3, 691-700). The nucleotide sequence of this nasmrtium xyloglucanase/XET enzyme has been determined and is disclosed in International Patent Application No. WO 93/17101 and by de Silva et al. , (1993 The Plant Journal 3, 701-711). Similar enzyme activity has been detected in other plant tissue and shown to be positively correlated with growth rate in different zones of the pea stem (Fry et al. , 1992 Biochem. J. 282, 821-829). It has been proposed that XET is responsible for cutting and rejoining intermicrofibrillar xyloglucan chains and that this causes the wall-loosening required for plant cell expansion. XET activity has also been demonstrated in tomato fruit (xyloglucanase apparently activatable by xyloglucan oligosaccharides) where it is reportedly highest at the 2 days post- "breaker" stage of ripening (Machlachlan & Brady, 1992 Aust. J. Plant Physiol. 19, 137-146) and may be involved in the softening process. This application describes the isolation from tomato plants of a nucleotide sequence which encodes an XET activity. Summary of the Invention In a first aspect the invention provides a polypeptide having xyloglucan endo-transglycosylase (XET) activity, comprising substantially residues 21-289 of the amino acid sequence of Figure 1 (Seq ID No. 2), or functional equivalents thereof. The term "functional equivalent" as used herein and applied to an amino acid sequence is intended to refer to those amino acid sequences having the same functional characteristics as the sequence of the invention but which have slightly different sequences. Generally, for example, it is well known that one may make a "conservative" substitution, exchanging one amino acid residue in a sequence for another residue with very similar properties, without having any significant effect on the function of the polypeptide. An example of a functionally equivalent polypeptide sequence is shown in Figure 5 (Seq ID No. 8). The amino acid sequences shown in Figures 1 and 5 are directly compared in Figure 6. Further, one or more amino acid residues may be deleted or added without significant deleterious effect. It will be apparent to those skilled in the art that such changes may particularly be made at points in the sequence which are not evolutionarily conserved. Enzyme precursors are also included within the meaning of "functional equivalents" and also mature, processed enzymes lacking signal sequences. In the present case amino acid residues 1-20 of Figure 1 are believed to constitute such a signal sequence and are therefore not essential for enzyme activity. Likewise, amino acid residues 1-18 of the sequence shown in Figure 5 are thought to comprise a non-essential signal sequence. In specific embodiments therefore the invention may provide a polypeptide having XET activity and comprising residues 1-289 of the sequence shown in Figure 1; or residues 19- 287 of the amino acid sequences shown in Figure 5; or residues 1-287 of the amino acid sequence shown in Figure 5. Preferably such functional equivalents will exhibit at least 80% homology, and more preferably at least 85% homology, and most preferably at least 90% homology, with the amino acid sequence of the invention. The present inventors have, by analysis of the amino acid sequence data, identified a number of peptide sequences which are thought to be relatively conserved within functional equivalents of the sequence of the invention. Preferably, functional equivalents will comprise substantially one or more of the following peptide sequences (which will generally be perfectly conserved but may contain up to one or, at most, two amino acid differences): DEIDFEFLGN; SLWNADDWAT; FYSKNEYLFG; and GTv TFYLSS; (Seq ID Nos. 3-6 respectively). Desirably the polypeptide is substantially in isolation from other plant derived substances. In a second aspect the invention provides a nucleotide sequence encoding the amino acid sequence of Figure 1 (Seq ID No. 1), or functional equivalents thereof. Preferably the nucleotide sequence comprises the nucleotide sequence of Figure 1 or other functionally equivalent sequences obtainable from tomato plants. The term "functional equivalent" as used herein and applied to nucleotide sequences is intended to refer to nucleotide sequences encoding a polypeptide having the same functional characteristics as the amino acid sequences of the first aspect and includes nucleotide sequences which will hybridise under standard conditions (described by Sambrook et al. 1989, Molecular Cloning: A Laboratory Manual) to the complement of the nucleotide sequence of Figure 1. Preferably the functionally equivalent nucleotide sequence will exhibit at least 70% homology, more preferably 80% homology and most preferably at least 85% homology with the nucleotide sequence of Figure 1. A specific example of a functionally equivalent nucleotide sequence is shown in Figure 5 (Seq ID No. 7). For the purposes of the present specification, the term "functional equivalent" also refers to "anti-sense" sequences which hybridise under standard conditions to the nucleotide sequence of Figure 1. Such sequences have utility in down-regulating the expression of the nucleotide sequence of the invention. Preferably such anti-sense functional equivalents will exhibit at least 70% homology, more preferably at least 80% homology, and most preferably at least 90% homology with the complement of the nucleotide sequence of Figure 1. In general, anti-sense functional equivalents will preferably exhibit higher percentage homology than sense equivalents. This is because sense constructs will be translated into polypeptides which will be functional and which may contain conservative amino acid substitutions. In contrast, anti-sense constructs will, in the vast majority of instances, function at the level of nucleic acid rather than polypeptide, and thus any base sequence differences will tend to reduce the usefulness of the construct. Those skilled in the an will understand that, with the benefit of the disclosure herein relating to the nucleotide and amino acid sequences of the invention, it will be simple to detect, isolate and clone (e.g. by PCR) other nucleotide sequences which are functionally equivalent to the nucleotide sequence of the invention. Suitable methods, for example, are taught by Sambrook et al. Of particular usefulness in such routine work may be the peptide sequences disclosed above. Also, the polypeptide of the invention (or peptides derived therefrom) may be used to generate antibodies for use in immunological screening of putative functionally equivalent sequences. It is preferred that the sequence of the second aspect of the invention further comprises a 5' untranslated region including a suitable promoter, to enable expression in host cells. The invention also provides a vector comprising the nucleotide sequence of the second aspect of the invention, and a host cell comprising the nucleotide sequence of the invention. In one embodiment, the vector is capable of expressing the nucleotide sequence, so as to produce the polypeptide of the invention. (Other vectors may comprise an antisense functionally equivalent nucleotide sequence). Thus, in a further aspect, the invention provides a method of producing a polypeptide having XET activity, comprising the steps of: introducing into a suitable host cell a vector capable of directing the expression of a polypeptide as defined above, growing the host cell and/or the progeny thereof in suitable culture conditions so that the polypeptide is expressed, followed by obtaining the polypeptide from either the culture medium and/or the host cells. It is preferable, but by no means essential, that the host cell is eukaryotic, as a eukaryotic host is more likely to express the enzyme in a fully functional conformation. Suitable vectors are known which can be used to introduce and express the sequence of the invention in plants. In a further aspect the invention provides a method of transforming a host cell, comprising the introduction into the host cell of the nucleotide sequence of the second aspect of the invention. Preferably the host cell is a plant cell. Preferably the transformed plant cell comprises part of a plant. As will be apparent to those skilled in the art, the introduction of the nucleotide sequence of the invention into a plant or part thereof would be expected to alter the characteristics of the plant or part thereof. In a still further aspect, the invention provides a method of altering the characteristics of a plant or part thereof, comprising introducing into the plant or part thereof an effective portion of the nucleotide sequence of the invention or a functional equivalent thereof, so as to alter the level of XET activity in the plant or part thereof. Preferably the method is such as to reduce the level of XET activity in the plant or part thereof, typically by introducing an antisense sequence. Preferably the effective portion will comprise at least 50%, more preferably at least 70%, and most preferably at least 90% of the nucleotide sequence of the invention? In another aspect, the invention provides a genetically engineered plant having characteristics altered by the method defined above, or the progeny of such a plant. The altered plant is preferably any commercially important plant (including fruit or vegetable plants) where there is sufficient knowledge to perform the method of the invention and in which xyloglucan has a structural function (i.e. dicots and non-Graminaceous monocots). Such plants include: alfalfa, apple, broccoli, cabbage, carrot, cauliflower, celery, cotton, cranberry, cucumber, eggplant, flax, grape, horseradish, kiwi, lettuce, mangoes, melon, oilseed rape, papaya, pea, peaches, pears, peppers, plum, poplar, potato, raspberry, soybean, spruce, strawberry, sugarbeet, sweet potato, tobacco, tomato and walnut. It will be appreciated that the characteristics of the whole plant need not be altered. It may be desirable to alter the properties of parts of the plant (e.g. seeds, fruit). This could be achieved, for example, by the use of tissue-specific promoters to regulate transcription of the introduced sequence. The method of the invention would be expected to alter levels of XET activity and thus the frequency of breaking and re-forming of cell wall cross-links (consisting of xyloglucan molecules) resulting in wall loosening which may permit cell expansion. Moreover, in view of the important structural role of xyloglucan, one might expect the characteristics which might be altered to include: size, rate of growth, and texture, especially during ripening. The invention is further described by reference to the following illustrative example and drawings, in which: Figure 1 shows an amino acid and nucleotide sequence (clone Bl) in accordance with the invention; Figure 2 shows partial amino acid sequences of a polypeptide in accordance with the invention and a functional equivalent thereof, compared with two prior art amino acid sequences; Figure 3 shows the sequencing strategy used to determine the sequence shown in Figure 1, (E = EcoRI, P = Pst, H = Hindm); Figure 4 shows the sequencing strategy used to determine the sequence of a nucleotide (clone B2) in accordance with the invention (E = EcoRI, P = Pst); Figure 5 shows a nucleotide sequence (clone B2) and amino acid sequence in accordance with the invention; Figure 6 shows a comparison of two functionally equivalent amino acid sequences (dot = identical amino acid; triangle = predicted cleavage site); and Figures 7 and 8 are schematic illustrations of various plasmid constructs. Examples Example 1 Following complete sequencing of a cDNA encoding nasmrtium seed XET (described in pending International Patent Application No. WO 93/17101), primers were designed to attempt PCR amplification of similar gene fragments from tomato. Two of the primers (NXG2H and NXG2B, shown below) overlapped with a region homologous to a Bacillus macerans ---1,3-1,4-glucanase (the region having the amino acid sequence DEIDIEFLG). The other primers corresponded to regions adjacent to or surrounding histidine residues; (these are often present in active sites of hydro lytic enzymes, and active sites of enzymes of similar function often having primary sequence homology). These corresponded to amino acid sequences PNHNRVD (primer NXGIH), HDEIDIE (primers NXGH2H and NXG2B), HLWFDPT (primers NXG3H and NXG3B) and TRDHTLT (primer NXG4B). NXGIH 5' AAGCTTCCTCAACATCAAAGGGTAGA 3' (sense) NXG2H AAGCTTCATGATGAAATCGATATTGA (sense) NXG2B GGATCCTCAATATCGATTTCATCATG (antisense) NXG3H AAGCTTCATTTATGGTTTGATCCAAC (sense) NXG3B GGATCCGTTGGATCAAACCATAAATG (antisense) NXG4B GGATCCGTTAACGTGTGGTCTCGTGT (antisense) (Seq ID Nos. 9-14, respectively) These primers were completely conserved with respect to the nasturtium sequence and incorporated restriction enzyme recognition sites at their 5' ends to facilitate cloning of PCR products. However all attempts to amplify tomato DNA by PCR, using any combination of the above primers, proved unsuccessful. The deduced amino acid sequence of nasturtium seed XET shares some regions of homology (42% identity in a 151aa overlap) with a sequence deduced from a genomic clone and cDNA from Arabidopsis thaliana (Medford et al., 1991 The Plant Cell 3, 359-370). The polypeptide encoded by the genomic clone is termed meri-5 and its function is currently unknown. It was decided to attempt PCR amplification of tomato DNA using a mixture of degenerate oligonucleotides (XG 117 and XG 162, shown below) corresponding to two of these regions conserved between nasturtium XET and meri-5, although there was little expectation of success in view of the previous failures and the lack of knowledge concerning the function (if any) of meri-5. Surprisingly, PCR succeeded in amplifying a 122bp tomato genomic DNA fragment having significant sequence homology to both meri-5 and nasturtium XET. The experiment was performed as described below. Genomic DNA was isolated from young tomato leaf tissue (cultivar VF 143B-7879, available from the Tomato Genetics Stock Centre, Department of Vegetable Crops, University of Califorma, Davis, CA95616), as described by Dellaporta et al. (1983, Plant Mol. Biol. 1, 19-21). The degenerate oligonucleotide mixtures were designed corresponding to the conserved regions DEID(I/F)EFLG (XG 117) and HLWFDPT (XG 162), as shown below: XG 117 5' GA(C/T) GA(A/G) ATI GA(C/T) (A/T)T(A C/T) GA(A/G) TT 3' (sense) XG 162 3' GT(G/A) (G/A)A(G/A/T/C) ACC AA(G/A) CT(G/A) GGI TG 5' (antisense) (Seq ID Nos. 15 and 16 respectively) The degenerate oligonucleotides were then used as primers in the following reactions (each reaction having a total reaction volume of lOOμl): l-2μg genomic DNA; 100 picomoles each of XG 117 and XG 162; dGTP, dATP, dTTP and dCTP all at 0.2mM; lOmM Tris-HCl pH 8.3; 50mM KC1; 1.5mM MgCl 2 ; 0.01 % (W/V) gelatin; and 2.5 units Taq DNA polymerase (Stratagene). Thermal cycling was carried out in an MJ Research programmable thermal controller with an initial denaturing step of 94 °C for 2 minutes, followed by 35 cycles of 94 °C for 1 minute, 40 °C for 2 minutes and 72 °C for 2 minutes. Amplification products were fractionated on a 2% agarose/TBE gel containing 0.5μg/ml ethidium bromide and viewed on a UV transilluminator. DNA fragments were purified from gels using DEAE paper, as described by Sambrook et al. (Molecular Cloning: a laboratory Manual). The main PCR product was found to be 122bp in size. This was ligated into pT7Blue (obtained from AMS Biotechnology) and subjected to DNA sequence analysis. Of the four clones sequenced, three had identical DNA sequences (PX3) and one differed in both DNA and deduced amino acid sequence (PXl), as shown in Figure 2. In Figure 2, Tom 3 and Tom 1 represent the deduced amino acid sequence for PX3 and PXl respectively, as compared with Meri-5 and nasturtium XET. In order to obtain more extensive sequence information, a tomato cDNA 5' stretch library was obtained from Clontech Laboratories Inc. (prepared using mRNA from the "breaker" stage of ripening fruit from tomato, "Ailsa craig" cultivar VFN8); this was primed with oligo-(dT) and random primers to synthesise cDNA, which was packaged in phage lambda gtn. Approximately 200,000 cDNA clones from this library were screened using the 122bp PCR fragment as a radiolabelled probe. Briefly, 25-30ng of gel-purified 122bp amplification product were denatured in 9μl H 2 0 by heating at 100°C for 5 minutes and then cooling on ice. The fragments were radio-labelled with 32 P-dCTP (Amersham International pic) using a kit supplied by United States Biochemicals Inc. (Sequenase v2.0). Unincorporated nucleotides were removed by chromatography through a Sephadex G-50 column. Using this probe, a number of positively-reacting clones were detected in the cDNA library. These were eluted from top layer agarose into 0.1 -lml SM (50mM Tris-HCl pH 7.5, lOmM MgS0 4 , lOOmM NaCl, 0.01 % w/v gelatin) and purified by further rounds of screening. The insert was isolated from the bacteriophage either by direct PCR of the stock suspension or by digestion of isolated DNA. For PCR of the stock suspension, purified bacteriophage stocks (5μl, lO O^fu) were heated at 100°C for 5 minutes and added to a solution identical to that described previously except that 20pmols each of gtll 5' and 3' oligonucleotides (Clontech) were used instead of the degenerate ones. Thermal cycling was as follows: 2 minutes at 94 °C, 25 cycles of 1 minute at 94°C, 1 minute at 55 °C and 2 minutes at 72°C, followed by a final step of 5 minutes at 72° C. Amplification products were gel-purified on 1 % agarose gels as above. Gel-purified PCR-amplified products were ligated into pT7 Blue PCR cloning vector (AMS Biotechnology Limited) and transformed into competent E. coli according to the manuf acturer ' s instructions . Colonies containing recombinant plasmids were used to inoculate 30ml Lennox broth containing 50μg/ml ampicillin and 12.5μg/ml tetracycline; after overnight growth at 37°C, purified plasmid DNA was obtained from the culture using a "Plasmid midi" kit supplied by Qiagen Inc. Restriction analysis of the cloned products was carried out using enzymes and buffers supplied by Amersham International pic, followed by agarose gel electrophoresis. DNA was sequenced using kits and protocols supplied by United States Biochemicals Inc. (Sequenase v2.0). Recombinant plasmids (Qiagen-prepared) were either sequenced directly or restriction fragments were subcloned into Ml 3 to produce single-stranded templates. Reaction products were fractionated on 30cm x 40cm x 0.4mm polyacrylamide gels using BRL 6% acrylamide solutions. An IBM computer with DNAstar software was used to analyse resultant sequences. Clones were found to vary in size between 500 and 1400 bp. One clone, termed clone tXΕT-Bl (or "Bl" for simplicity), was found to possess internal Hindlll and Sad recognition sites which facilitated subcloning into M13. Internal primers were also used in order to sequence the clone fully and in both directions (Fig. 3). The sequences of these internal primers (8-TH, 8-HS sense primers and 8-TB, 8-HT antisense primers) are as follows: 8-TH: 5' CGATGCAGCTGGAATTTCA 3' 8-TB: 5' AGTTTGAGCTGCATATCGAA 3' 8-HS: 5' TTTGATCCCACCTCGCCGTT 3' 8-HT: 5' CAGCTGACCAAACACAAGCA 3' (Seq ID Nos. 17-20 respectively) The sequences of the other primers were:- T3: 5' ATTAACCCTCACTAAAGGGA 3' T7: 5' TAATACGACTCACTATAGGG3' U19: 5' GTTTTCCCAGTCACGACGT 3' (Seq ID Nos. 21-23 respectively) U represents the M13 (-40) primer. Initially, two sequences were found, each from a different PCR amplification from the lambda stock. They differed in 2 base pairs within the putative coding region. Since these differences were probably due to die inaccuracy of the thermostable DNA polymerase used in the PCRs, lambda DNA was prepared and the cDNA ligated into pBluescript SK+, in order to obtain definitive sequence data (Fig. 1). The definitive nucleotide sequence of clone Bl is shown in Figure 1, together with the deduced amino acid sequence. The putative open reading frame of clone Bl encodes a 289 amino acid polypeptide of predicted molecular weight 32.7kDa. This has 39% identity in 270 overlapping amino acids with nasturtium XET and 59% identity in an overlap of 186 amino acids with meri-5. A signal peptide is predicted on the basis of hydrophobicity of amino acids in positions 1-25, and statistical analysis of the amino acid sequence predicted that the precursor is cleaved between alanine and aspartate residues at positions 20 and 21 (Von Heijne, 1983 Eur. J. Biochem. U3, 17-21). The region of clone Bl corresponding to the genomic PCR fragments (aa 103-129) shows differences in the deduced amino acid sequence compared to both of the genomic fragment sequences. This suggests that clone Bl is part of a multi-gene family in tomato. A putative N-glycosylation site (Asn-X-Ser/Thr ; aa 105-107) was identified, which is also present in meri-5 and the genomic fragments, but not nasturtium XET. The second clone obtained, termed clone tXET-B2 (abbreviated to "B2"), was larger than clone Bl but had no convenient restriction sites for subcloning, so several internal primers were used to complete DNA sequencing. The strategy used to determine the sequence of clone B2 is shown schematically in Figure 4. In figure 4, E = EcoRI site, P == Pstl site; (a) shows sequencing using vector primers, (b) and (c) shows sequencing with internal primers. A number of primers were employed, including: 16-1 : 5' AATATCAGCGGAAACAGGG 3 * 16-1R: 5' CCCTGTTTCCGCTGATAATT 3' . 16-2: 5' CTATTAGCATCTGCACAGTA 3' 16-2R: 5' TACTGTGCAGATGCTAATAG 3' 16-3R: 5' GGAGGACGGGTGAAGACAGA 3' 16-4: 5' GTGTAAGGTAGTCCTGATGA 3' 16-4R: 5' TCATCAGGACTACCTTACAC 3' (Seq ID Nos. 24-30 respectively) A deduced open reading frame of 287 amino acids was identified. The determined nucleotide sequence and deduced amino acid sequence of clone B2 are shown in Figure 5. Figure 6 shows the cDNA sequence of clone Bl and deduced amino acid sequence thereof, in direct comparison with the deduced amino acid sequence for clone B2. (In Figure 6, dots indicate identical amino acids, and the arrow indicates the predicted signal peptide cleavage site.) The predicted signal peptide for clone B2 was 2 amino acids shorter than that of clone Bl, leaving a mature polypeptide of 269 amino acids. A putative N- glycosylation site was found in the same position as for clone Bl. Sixteen amino acid differences between the predicted mature polypeptides of clones 8 and 16 were identified, 14 of which were conservative. Hydrophobic Cluster Analysis (HCA, as described by Gaboriaud et al. , 1987 FEBS Letters 224. 149-155 and Henrissat et al., 1988 Biochem. J. 255, 901-905) was performed to investigate possible conformational homology of the polypeptide encoded by clone Bl with other known proteins. HCA plots were produced from the deduced amino acid sequences of nasturtium XET, meri-5 and tomato clone Bl using WordPerfect™ 5.1 macros, using a modified 2D representation of an α-helix (Henrissat et al, cited above). Hydrophobic clusters were encircled by hand, aligned manually and HCA homology scores calculated. Similar folding was predicted for all three proteins on the basis of (a) "continuous presence of conserved clusters" throughout most of the length of the sequence and (b) overall HCA homology scores for all three comparisons being more than 75% (meri-5 v. tomato XET clone Bl, 86%; nasturtium XET v. tomato XET clone Bl, 80% ; meri-5 v. nasturtium XET, 78%). This supports data from primary sequence homology and secondary structure predictions (Kyte & Doolittle 1982, J Mol Biol 157, 105-132) which suggest that these three proteins are likely to have broadly similar folding and therefore similar function, whilst differing in detail. It was decided to attempt to express clone B2 in E. coli. This is described below in Example 2. Example 2 Manipulation of Clone B2 for expression in E. coli A BamHl recognition sequence was introduced close to the N-terminal coding sequence of the putative mature protein by PCR, using a mutagenic primer (16-1 B: CCCTTGGATCCGCTATAATT Seq ID No. 31) and a pBluescript primer (T3; Stratagene). Reaction conditions were: lng XET clone B2 in pBluescript SK+, 0.4mM each of dATP, dCTP, dGTP and dTTP, 25 pmols of each primer, 1 x VENT polymerase buffer and 0.25 units VENT DNA polymerase (New England Biolabs Inc.). Thermal cycling was 2 minutes at 93°C, 25 cycles of 1 minute at 93 °C, 30 seconds at 55 °C and 1 minute at 72 °C. Over-expression of recombinant tomato XET in E. coli Expression of tomato XET in E. coli was achieved using the QIAGEN QIAexpress™ system. A BamHI-HindTII fragment of the mutagenised PCR product was ligated into the expression vector pQE30 and transformed into E. coli M15 cells containing the pREP4 repression plasmid. The expression vector allows incorporation of a 6 x histidine tagged N-terminal which has high affinity for Ni-NTA (Ni-NTA is nickel-nitrilo tri-acetic acid) resin provided by QIAGEN. Cells were grown in Lennox broth containing appropriate antibiotics and induced with 2mM IPTG when the optical density of the culture at 600nm was 0.7-0.8. Growth was then allowed to continue for 3-5 hours. For analysis, cells were pelleted from 0.5ml of the culture, boiled in sample buffer (Laemmli 1970 Nature 227. 680-685) and run on SDS-polyacrylamide gels (10%); separated proteins were stained in Coomassie blue. Localisation of tagged proteins was established as in protocol 4 of "The QLAexpressionist" 2nd edition (1992; QIAGEN Inc.). Recombinant tomato XET protein purification and refolding Recombinant tomato XET was purified under denaturing conditions on Ni-NTA resin as described in "The QIAexpressionist" protocol 7, except that after the final wash, the column with bound protein was equilibrated in 6M urea, 0.5M NaCl, 20% glycerol, 40mM Tris-HCl pH7.4. An FPLC-mediated 6M-1M urea gradient (24ml at a rate of 0.25ml min) in the above solution was then used to refold the bound protein, which was eluted in 10ml IM urea, 0.5M NaCl, 20% glycerol, 40mM Tris-HCl pH7.4, 250mM imidazole. Assays for XET activity 3 H-labelled XG oligosaccharides were obtained from S C Fry, (University of Edinburgh) and their incorporation into polymeric XG assayed as described by Fry et al. (1992 Biochem. J. 261, 9489-9494). Protein concentration was estimated using a kit supplied by BioRad. N-terminal amino acid sequencing Purified recombinant proteins were subjected to electrophoresis as above, using high quality reagents. They were then electroblotted (0.5A, 2 hours) onto Problott™ membrane (a derivatised PVDF material, obtained from ABI) and stained in 1 % Coomassie Brilliant Blue, 50% methanol. The blotted protein was subjected to sequential Edman degradation on an ABI gas phase sequencer model 740, with pulse liquid update, as described by Cottingham et al. (1988 Biochim. Biophys. Acta 956, 201-207). Expression and characterisation of recombinant tomato XET Tomato XET was expressed in E. coli with an N-terminal 6 x His tag to facilitate purification. A tagged protein of the predicted molecular weight (32kDa) was found in the insoluble fraction; phase contrast microscopy of the expressing culture showed strongly refracting bodies in each cell, suggesting the presence of insoluble inclusion bodies (data not shown). Following large-scale purification under denaturing conditions, the tagged protein was subjected to N-terminal amino acid sequencing. The resulting sequence (MRGSHHHHHHGSADNFYQDA Seq ID No. 32) confirmed both the identity of the protein as recombinant tomato XET, and the presence of the N-terminal 6 x His tag. Recombinant tomato XET was refolded whilst bound to the Ni-NTA agarose resin, by a reverse urea gradient. Following elution from the column, 15μl was assayed for incorporation of 3 H-XG oligosaccharides (XGOs) into polymeric XG: approximately 400 Bq of 3 H-XGOs were incorporated per kBq provided, per hour, per μg protein. Following dialysis against 0.5M NaCl, 50mM Tris-HCl pH7.2, 20% glycerol, specific activity increased to approximately 700 Bq/kBq hour μg. Clone B2 was thus over-expressed in E. coli with the apparent N-terminal signal peptide replaced with a 6 x histidine tag which facilitated purification. Following purification and refolding, the recombinant protein was able to catalyse incorporation of radiolabelled XG oligosaccharides into polymeric XG, confirming it as an XET. The specific activity of the refolded XET is relatively low; a crude stem extract from a growing tomato plant has an XET specific activity of about 100 Bq/kBq hour μg, compared to 700 Bq/kBq μg for refolded XET. Since the recombinant protein is greater than 90% pure, this is presumably due to most of the protein not being correctly refolded. Unlike nasturtium seed XET, a putative N-glycosylation site is present in both clones' amino acid sequences. It is interesting to note that, recombinant expression in E. coli, which does not glycosylate proteins, resulted in active XET. This shows that the glycosylation is not necessary for XET activity in vitro, raising questions about its role in vivo. The lack of glycosylation in nasturtium seed XET may reflect its specialist role in storage reserve mobilisation. Evidence for the function of XET in plants is rapidly accumulating. The hypothesis that XET plays a role in plant growth is supported by its correlation with growth along the length of pea stems (Fry et al, 1992 Biochem. J. 282, 821-828) and in maize roots (Pritchard et al, 1993 J. Exp. Bot. 44 1281-1289). It is thought to act by loosening the cell wall to permit cell expansion. XET is also likely to be involved in fruit ripening, as suggested by its changing levels in fruits as diverse as tomato, pear (unpublished observations of the inventors) and kiwi (Fry 1993 Current Biology, 3 (no. 6), 355-357). Here XET may improve access of other enzymes to the tightly packed networks of the cell wall. This would be supported by the small, compact nature of XET (Edwards et al., 1986 J. Biol. Chem. 261, 9489-9494). Alternatively, XET may be involved (possibly in conjunction with other cell wall hydrolases) in the depolymerisation of xyloglucan which occurs during fruit ripening. Example 3 In addition to the recombinant DNA work described above, attempts were made to isolate and purify a polypeptide having XET activity from tomato plants. Step 1 : Assay for activity of XET XET activity in various crude tomato fruit extracts was measured by incorporation of 3 H-labelled xyloglucan oligosaccharides into xyloglucan polymer. This assay measures transglycosylase activity. Each assay contained the following components: lOμl 0.2M Na-Mes, pH 6.0 (Na-Mes is Na 2-[N-Morpholino] ethanesulphonic acid), lOμl 8 mg/ml xyloglucan, and 5μl [ 3 H] XGO (0.7 KBq). Assays were incubated at 25 °C for 1 hour, and stopped by addition of 100 μl 20% formic acid. The assay mixture was then spotted onto a 5 x 5 cm disc of cellulose filter paper (Whatman 3MM Chromatography paper). It has been established that xyloglucan polymer (whether labelled or unlabelled with [ 3 H]XGO) will bind to the cellulose filter, whereas [ 3 H]XGO oligosaccharides will not. The filters were allowed to dry and unincorporated [ 3 H]XGO was removed by washing under running tap water for 30 min. The filters were dried again at 60°C, then rolled, loaded face outwards, into a cylinder and placed in a 22ml scintillation vial. Scintillant (2ml of Betamax ES) was added and the filters counted for 3 H. This assay is essentially as described by Fry et al. (1992), cited above. Step 2: Extraction of XET from tomato pericarp A variety of extraction buffers were used and their effectiveness assessed. It was found that XET was efficiently extracted by 0.1 M sodium phosphate buffer, pH 7.2. It was also found that retention of XET activity was highly dependent on ionic strength, and activity was lost if the ionic strength of chromatography buffer etc. was less than 0.2M. Step 3: Choice of starting material for purification Crude extracts were made (in 0.1 M sodium phosphate buffer, pH 7.2) from tomato pericarp (Lycopersicum esculentum, var. Moneymaker) tissues taken from all stages of growth and ripening. It was consistently found (from several experiments) that small green fruit (i.e. less than 35mm in diameter) had the highest XET activity, whether expressed as total or specific activity. Therefore the pericarp of small green fruit was used as the starting material for purification. Step 4: Ammonium sulphate precipitation Pericarp tissue (lOOg) from small green fruit of less than 35mm in diameter was harvested, frozen in liquid nitrogen, and stored at -20 °C or -70 °C. The tissue was homogenised in 1 g: 1.5 vol 0.1 M sodium phosphate, pH 7.2 with 1.0% (w/v) insoluble PVP (poly vinyl pyrrolidone) in a blender. The homogenate was stirred for 1 hour at 4°C to allow diffusion of cell wall enzymes. Insoluble material was removed by centrifugation at 20,000g, 30 minutes, 4°C in the SS34 rotor of the Sorvall RC5B centrifuge. The supernatant was passed through glasswool, and brought to 90% ammonium sulphate saturation by addition of solid ammonium sulphate (60.3 g/lOOml). The mixture was stirred for 40 min at 4°C, and the precipitated proteins collected by centrifugation (38,000g, 30 minutes, 4°C). The ammonium sulphate precipitated proteins were stored at -20°C without resuspension. Step 5: S-sepharose cation exchange chromatography 0-90% ammonium sulphate precipitated proteins were resuspended in 10ml 50 mM sodium acetate buffer, pH 5.3 with 0.2 M NaCl (Buffer A) containing 1 mM EDTA, 20 μg/ml chymostatin, 1 mM PMSF. The resuspended pellet was dialysed for 2 hours against 2.5 1 of Buffer A using 3,500 M r -cut off dialysis tubing. The sample was diluted with 50 mM sodium acetate buffer pH 5.3, 1 mM EDTA to bring the conductivity down to a suitable value for loading onto the S-Sepharose column. The sample was centrifuged at 38,000g for 15 minutes, 4°C, then loaded onto a 7ml S-Sepharose Fast Flow column (Pharmacia) equilibrated in Buffer A. The column was washed with Buffer A (flow rate lml/minute) until all unbound proteins were removed. Bound proteins were eluted with a 0-100% gradient of Buffer B (as Buffer A, but with 1 M NaCl) over 10 column volumes. Fractions (2 ml) were collected and assayed for XET activity. Step 6: Concanavalin A affinity chromatography Fractions from S-sepharose ion exchange chromatography with high XET activity were pooled and stored at -20°C. Prior to concanavalin chromatography, the fractions were brought to 1 mM MgCl 2 and MnCl 2 . The S-Sepharose pool was centrifuged and the supernatant loaded onto a Concavalin-A column equilibrated in 50 mM sodium acetate buffer pH 5.7 containing 0.2 M NaCl, 1 mM MgCl 2 , 1 mM CaCl 2 and 1 mM MnCl 2 (Buffer C). Bound proteins were eluted from the column with a single step elution with Buffer D (as Buffer C plus 0.5 methyl α-D-mannopyranoside). Fractions collected were assayed for XET activity. Step 7: N-terminal amino acid sequencing Samples from the Concanavalin A column with high XET activity were separated according to apparent molecular weight on a 15% SDS polyacrylamide gel. After electrophoresis, proteins were transferred onto the Problott™ membrane (transfer buffer: 10 mM CAPS pH 11 in 10% methanol). The Problott™ membrane was stained in 0.1 % Coomassie Brilliant Blue R250 in 1 % acetic acid, 40% methanol and destained in 50% methanol. A single band (i.e. the protein had been successfully purified to homogeneity) of approximate M r 36,000 was visible; this was excised and subjected to N-terminal amino acid sequencing on an ABI model 475 protein sequencer. The sequence determined (Seq ID No. 33) was: GYPRRPVDVPFWKNY. The level of the sequence was consistent with the intensity of the stained protein band. In another aspect therefore, the invention provides a substantially pure polypeptide with xyloglucan endotransglycosylase (XET) activity with an apparent molecular weight of 36kDa, as judged by SDS-PAGE. Preferably the enzyme is obtainable from tomato plants, most preferably from the pericarp of green tomato fruit, and preferably has substantially the N-terminal amino acid sequence GYPRRPVDVPFWKNY. The enzyme is preferably purified by one or more of ammonium sulphate precipitation, ion exchange chromatography and/or concanavalin A affinity chromatography. Example 4 Expression of XET in tomato The XET assay described above has been used to monitor XET activity throughout the tomato plant (var. Moneymaker). Extracts (0.2M phosphate) were prepared from root, leaf and petiole segments isolated from different parts of the growing plant and fruit at four stages of development and three stages of ripening. Highest XET activity was recorded in extracts prepared from petioles isolated from the top of the growing plant and developing (small green) fruit, consistent with XETs involvement in plant growth. Total RNA was extracted from different parts of the tomato plant using a Qiagen extraction procedure. tXET-Bl (tomato XET clone Bl) transcript levels were determined by RNAse protection analysis. An antisense tXET-Bl specific probe was synthesised by incubating Hindϋl linearised ptXET-Bl plasmid with lμl T3 RNA polymerase in the presence of 0.5mM rATP/rGTP/rCTP,5nM UTP, 50μCi 32 P-UTP (800Ci/mmol), lμl RNase inhibitor and 2μl reaction buffer (Ambion probe synthesis kit) in a final reaction volume of 20μl for 1 hour at 25 °C. Following DNase digestion and phenol/chloroform extraction, probe was recovered by ethanol precipitation. lO^pm labelled probe was incubated with 5μg total RNA and RNase protection analysis carried out using an RPAII kit supplied by Ambion. Protected probe was quantified by denaturing gel electrophoresis followed by analysis on a Molecular Dynamics Phosphorlmager. Highest levels of tXET- Bl transcripts were detected in fruit pericarp, with levels in increasing through ripening and peaking in pink fruit. Maximum levels in stem (equivalent to levels seen in mature green fruit) were found approximately 10cm from the top of a 30cm plant. Lower levels of tXET-Bl transcript were detected in leaf with negligible levels in root. The differences in the patterns of activity and transcript level suggest either that total XET activity is encoded by a set of differentially expressed genes or tiiat selective isolation of isoforms is occurring at 0.2M phosphate. The pattern of expression of tXET-Bl suggests that this isoform may be involved in fruit ripening. Example 5 Reduction of XET enzyme levels in transgenic tomato plants A constitutive 2' mannopine synthase promoter was recovered on a Bglll fragment from the plasmid pSLJ2'Lnos, and ligated into the plasmid ptXET-Bl . (pSLJ2'Lnos was derived from pSLJ1006 [Jones et al. , 1992 transgenic Research 1, 285-297] by replacing the DNA sequence encoding a j3-glucuronidase enzyme with a polylinker sequence). This placed the tXET-Bl coding sequence in the antisense orientation with respect to, and downstream of, the 2' promoter (Figure 7). An Xba - Sst fragment containing the promoter and 798bp (nucleotides 187 to 984) of tXET-Bl sequence was then cloned into the plant transformation vector, pGPTV-kan (Becker D. et al., 1992, Plant Molecular Biology 20, 1195-1197 and Figure 8). The resultant plasmid, pGPTV-kan-2'tXET-Bl was used to transform Agrobacterium LBA4404 and the recombmant agrobacterium strain used to infect cotyledonary segments of tomato (variety Moneymaker). Transformed plants were selectively regenerated in the presence of kanamycin. The presence of the transferred DNA was confirmed by PCR amplification of a DNA segment between the primers NPTIIb (5' ATCGGGAGCGGCGATACCGTA 3', Seq ID No. 34) and 8-HS (see above). XET activity was monitored in extracts prepared from pink fruit (15 plants) by the method described above. Levels were reduced by up to approximately 80% in plants transformed with an antisense tXET construct. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: (A) NAME: Unilever PLC (B) STREET: Unilever House. Blackfriars (C) CITY: London (E) COUNTRY: United Kingdom (F) POSTAL CODE (ZIP): EC4P 4BQ (G) TELEPHONE: (0234) 222268 (H) TELEFAX: (0234) 222633 (A) NAME: Unilever NV (B) STREET: Weena 455 (C) CITY: Rotterdam (E) COUNTRY: Netherlands (F) POSTAL CODE (ZIP): 3013 AL (ii) TITLE OF INVENTION: Novel Plant Enzyme (iii) NUMBER OF SEQUENCES: 34 (iv) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentln Release #1.0. Version #1.25 (EPO) (2) INFORMATION FOR SEQ ID NO: 1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 994 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iii) ANTI-SENSE: NO (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 79..945 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1: GAAGTAGACG ATGCAGCTGG AATTTCAAAC ATACATTCCC AAAAACAACT AACTACATAT 60 TCCTTAAGAT πCCTATA ATG πG CTG CAG CAG CTA TCT Gπ Cπ GCT CTA 111 Met Leu Leu Gin Gin Leu Ser Val Leu Ala Leu 1 5 10 cπ CTC πG CTA TGT CCT Gπ TGG GCT GAC AAT πc TAC CAA GAT GCA 159 Leu Leu Leu Leu Cys Pro Val Trp Ala Asp Asn Phe Tyr Gin Asp Ala 15 20 25 ACG Gπ ACC πT GGT GAT CAG CGA GCT CAG ATA CAA GAT GGT GGG CGC 207 Thr Val Thr Phe Gly Asp Gin Arg Ala Gin He Gin Asp Gly Gly Arg 30 35 40 cπ CTC GCC πG TCC cπ GAC AAA Aπ TCA GGT TCA GGA Tπ CAG TCT 255 Leu Leu Ala Leu Ser Leu Asp Lys He Ser Gly Ser Gly Phe Gin Ser 45 50 55 AAG AAT GAA TAT πA πT GGA AGG πC GAT ATG CAG CTC AAA CTA GTA 303 Lys Asn Glu Tyr Leu Phe Gly Arg Phe Asp Met Gin Leu Lys Leu Val 60 65 70 75 CCT GGA AAT TCT GCT GGC ACT GTC ACT ACC πC TAT πG TCT TCT CAA 351 Pro Gly Asn Ser Ala Gly Thr Val Thr Thr Phe Tyr Leu Ser Ser Gin 80 85 90 GGA GCA GGG CAC GAC GAA Aπ GAT ITT GAG Tπ CTG GGA AAT TCA TCA 399 Gly Ala Gly His Asp Glu He Asp Phe Glu Phe Leu Gly Asn Ser Ser 95 100 105 GGC CAA CCG TAC ACG Gπ CAT ACT AAT GTC TAC TCT CAA GGA AAA GGC 447 Gly Gin Pro Tyr Thr Val His Thr Asn Val Tyr Ser Gin Gly Lys Gly 110 115 120 AAC AAA GAA CAA CAG Tπ CGC CTA TGG ITT GAT CCC ACC TCG CCG πC 495 Asn Lys Glu Gin Gin Phe Arg Leu Trp Phe Asp Pro Thr Ser Pro Phe 125 130 135 CAC ACC TAC TCT Aπ Gπ TGG AAC TCT CAA CGC ATC ATA TTT πG GTG 543 His Thr Tyr Ser He Val Trp Asn Ser Gin Arg He He Phe Leu Val 140 145 150 155 GAT AAT ATC CCA ATA AGA GTA πC AAC AAC CAC GAA AAG Cπ GGT Gπ 591 Asp Asn He Pro He Arg Val Phe Asn Asn His Glu Lys Leu Gly Val 160 165 170 GCA πC CCA AAG AAC CAA GCA ATG AGA Gπ TAT GCC AGT πA TGG AAT 639 Ala Phe Pro Lys Asn Gin Ala Met Arg Val Tyr Ala Ser Leu Trp Asn 175 180 185 GCT GAT GAC TGG GCA ACA CAA GGA GGG CGA GTG AAG ACG GAT TGG TCA 687 Ala Asp Asp Trp Ala Thr Gin Gly Gly Arg Val Lys Thr Asp Trp Ser 190 195 200 ATG GCT CCG Tπ ACA GCT TCT TAC AGG AAT πC AAC ACA AAT GCT TGT 735 Met Ala Pro Phe Thr Ala Ser Tyr Arg Asn Phe Asn Thr Asn Ala Cys 205 210 215 Gπ TGG TCA GCT GCA TCG TCT ACT TCG TCC TGT GGA GGC TCT AAG ACT 783 Val Trp Ser Ala Ala Ser Ser Thr Ser Ser Cys Gly Gly Ser Lys Thr 220 225 230 235 GAT TCA GTA AAC AAT GAT CAG GCA TGG CAA ACT CAA GAA CTG AAC GGT 831 Asp Ser Val Asn Asn Asp Gin Ala Trp Gin Thr Gin Glu Leu Asn Gly 240 245 250 AAT GAC AGA AAT AGG Cπ CGA TGG Gπ CAG CAG AAA TAC ATG ATC TAC 879 Asn Asp Arg Asn Arg Leu Arg Trp Val Gin Gin Lys Tyr Met He Tyr 255 260 265 AAT TAC TGT GCA GAT GCT AAA AGG πC TCT CAA GGC Cπ TCT CCT GAA 927 Asn Tyr Cys Ala Asp Ala Lys Arg Phe Ser Gin Gly Leu Ser Pro Glu 270 275 280 TGC AAA CGT TCA AGG πC TAAAGGATCA AATCTACGAA TGπGTCTGT 975 Cys Lys Arg Ser Arg Phe 285 AATAπATCC CGGAAπCC 994 (2) INFORMATION FOR SEQ ID NO: 2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 289 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2: Met Leu Leu Gin Gin Leu Ser Val Leu Ala Leu Leu Leu Leu Leu Cys 1 5 10 15 Pro Val Trp Ala Asp Asn Phe Tyr Gin Asp Ala Thr Val Thr Phe Gly 20 25 30 Asp Gin Arg Ala Gin He Gin Asp Gly Gly Arg Leu Leu Ala Leu Ser 35 40 45 Leu Asp Lys He Ser Gly Ser Gly Phe Gin Ser Lys Asn Glu Tyr Leu 50 55 60 Phe Gly Arg Phe Asp Met Gin Leu Lys Leu Val Pro Gly Asn Ser Ala 65 70 75 80 Gly Thr Val Thr Thr Phe Tyr Leu Ser Ser Gin Gly Ala Gly His Asp 85 90 95 Glu He Asp Phe Glu Phe Leu Gly Asn Ser Ser Gly Gin Pro Tyr Thr 100 105 110 Val His Thr Asn Val Tyr Ser Gin Gly Lys Gly Asn Lys Glu Gin Gin 115 120 125 Phe Arg Leu Trp Phe Asp Pro Thr Ser Pro Phe His Thr Tyr Ser He 130 135 140 Val Trp Asn Ser Gin Arg He He Phe Leu Val Asp Asn He Pro He 145 150 155 160 Arg Val Phe Asn Asn His Glu Lys Leu Gly Val Ala Phe Pro Lys Asn 165 170 175 Gin Ala Met Arg Val Tyr Ala Ser Leu Trp Asn Ala Asp Asp Trp Ala 180 185 190 Thr Gin Gly Gly Arg Val Lys Thr Asp Trp Ser Met Ala Pro Phe Thr 195 200 205 Ala Ser Tyr Arg Asn Phe Asn Thr Asn Ala Cys Val Trp Ser Ala Ala 210 215 220 Ser Ser Thr Ser Ser Cys Gly Gly Ser Lys Thr Asp Ser Val Asn Asn 225 230 235 240 Asp Gin Ala Trp Gin Thr Gin Glu Leu Asn Gly Asn Asp Arg Asn Arg 245 250 255 Leu Arg Trp Val Gin Gin Lys Tyr Met He Tyr Asn Tyr Cys Ala Asp 260 265 270 Ala Lys Arg Phe Ser Gin Gly Leu Ser Pro Glu Cys Lys Arg Ser Arg 275 280 285 Phe (2) INFORMATION FOR SEQ ID NO: 3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 amino acids (B) TYPE: amino acid (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: YES (iii) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3: Asp Glu He Asp Phe Glu Phe Leu Gly Asn 1 5 10 (2) INFORMATION FOR SEQ ID NO: 4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 amino acids (B) TYPE: amino acid (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: YES (iii) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4: Ser Leu Trp Asn Ala Asp Asp Trp Ala Thr 1 5 10 (2) INFORMATION FOR SEQ ID NO: 5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 amino acids (B) TYPE: amino acid (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: YES (iii) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5: Phe Tyr Ser Lys Asn Glu Tyr Leu Phe Gly 1 5 10 (2) INFORMATION FOR SEQ ID NO: 6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 amino acids (B) TYPE: amino acid (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: YES (iii) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6: Gly Thr Val Thr Thr Phe Tyr Leu Ser Ser 1 5 10 (2) INFORMATION FOR SEQ ID NO: 7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1289 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iii) ANTI-SENSE: NO (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 232..1092 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7: GAAπCTGGG TAGGCπTGG πGCAATAAG CGTCTGπCT TCGCπACTA CπTGGAAAA 60 AπGACπTA GGCCTGCGGT CCCTAGCAπ AAAπCATCG ACCGCTGTGT CATATAGACG 120 CCGCTTTGCA AGATCGπGA CCAAGGTAπ GπACCTCGG ACGGTCTCAA GCAAAGCGGA 180 CGATGTGGCT GπTGTGTGT ATGCCAπGT AGπGTAGAA TGTAAAATAT A ATG πG 237 Met Leu 1 CTG CAG Cπ TCT Cπ Cπ ACA CTA GTC πA CTA TCC CCT Gπ TCC GCT 285 Leu Gin Leu Ser Leu Leu Thr Leu Val Leu Leu Ser Pro Val Ser Ala 5 10 15 GAT AAT πC TAC CAA GAC GCG GCG GTC ACG Tπ GGT GAC CAG CGC GCT 333 Asp Asn Phe Tyr Gin Asp Ala Ala Val Thr Phe Gly Asp Gin Arg Ala 20 25 30 CAG ATA CAA GAT GGA GGG CGC Cπ CTC ACA πG TCA Cπ GAT AAA Aπ 381 Gin He Gin Asp Gly Gly Arg Leu Leu Thr Leu Ser Leu Asp Lys He 35 40 45 50 TCA GGT TCC GGA Tπ CAG TCT AAG AAT GAG TAT πA πC GGA AGG πC 429 Ser Gly Ser Gly Phe Gin Ser Lys Asn Glu Tyr Leu Phe Gly Arg Phe 55 60 65 GAT ATG CAG Cπ AAA CTC GTA CCT GGA AAT TCT GCT GGC ACT GTC ACC 477 Asp Met Gin Leu Lys Leu Val Pro Gly Asn Ser Ala Gly Thr Val Thr 70 75 80 ACA πC TAT πG TCT TCT CAA GGA GCA GGG CAT GAT GAA Aπ GAT Tπ 525 Thr Phe Tyr Leu Ser Ser Gin Gly Ala Gly His Asp Glu He Asp Phe 85 90 95 GAG Tπ CTA GGA AAT TCA TCA GGA CTA CCT TAC ACG Gπ CAT ACC AAT 573 Glu Phe Leu Gly Asn Ser Ser Gly Leu Pro Tyr Thr Val His Thr Asn 100 105 110 Gπ TAC TCT CAA GGA AAA GGC AAT AAA GAA CAA CAA Tπ CGT CTC TGG 621 Val Tyr Ser Gin Gly Lys Gly Asn Lys Glu Gin Gin Phe Arg Leu Trp 115 120 125 130 Tπ GAT CCA ACT TCG TCG πC CAC ACT TAC TCT Aπ Gπ TGG AAC TCT 669 Phe Asp Pro Thr Ser Ser Phe His Thr Tyr Ser He Val Trp Asn Ser 135 140 145 CAA CGG ATC ATA Tπ πG GTG GAT AAT ATC CCA Aπ AGA GTG πC AAC 717 Gin Arg He He Phe Leu Val Asp Asn He Pro He Arg Val Phe Asn 150 155 160 AAC CAC GAA GCA Cπ GGT Gπ GCA TAC CCA AAG AAT CAA GCA ATG AGA 765 Asn His Glu Ala Leu Gly Val Ala Tyr Pro Lys Asn Gin Ala Met Arg 165 170 175 Gπ TAC GCG AGT CTA TGG AAT GCT GAT GAT TGG GCT ACA CAA GGA GGA 813 Val Tyr Ala Ser Leu Trp Asn Ala Asp Asp Trp Ala Thr Gin Gly Gly 180 185 190 CGG GTG AAG ACA GAT TGG TCT ATG GCT CCG TTT ACA GCT TCT TAC AGG 861 Arg Val Lys Thr Asp Trp Ser Met Ala Pro Phe Thr Ala Ser Tyr Arg 195 200 205 210 AAT πC AAT ACA AAT GCT TGT Gπ TGG TCA GCT GCT ACG TCT ACT TCG 909 Asn Phe Asn Thr Asn Ala Cys Val Trp Ser Ala Ala Thr Ser Thr Ser 215 220 225 TCT TGT GGA GGT TCT AAG ACT GAG TCA GTA AAC AAT GAT GAG ACA TGG 957 Ser Cys Gly Gly Ser Lys Thr Glu Ser Val Asn Asn Asp Glu Thr Trp 230 235 240 CAA ACG CAA CAA CTG AAC GCT AAT GGA AGA AAT AGA ATA CGA TGG Gπ 1005 Gin Thr Gin Gin Leu Asn Ala Asn Gly Arg Asn Arg He Arg Trp Val 245 250 255 CAG CAG AAG TAC ATG ATC TAC AAT TAC TGT GCA GAT GCT AAT AGG πC 1053 Gin Gin Lys Tyr Met He Tyr Asn Tyr Cys Ala Asp Ala Asn Arg Phe 260 265 270 TCT CAA GGC TTT TCT CCT GAA TGC AAG CGT TCA AGG πc TAAGGCGGAT 1102 Ser Gin Gly Phe Ser Pro Glu Cys Lys Arg Ser Arg Phe 275 280 285 ATATATAGTA TATGAATGTA AAAπATGπ TGTπCACπ πCTAπcπ πAAππGA 1162 TCAGGTAAAA AAAAAAAAGA ACATAGTGTA AπAπTGTG TATGCAATAT AπcπTAπ 1222 CππTGTAA TCATGAAATA GAAATAATAA TGAAπGπT TCCTGAAAAA AAAAAAACCG 1282 GAAπCC 1289 (2) INFORMATION FOR SEQ ID NO: 8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 287 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8: Met Leu Leu Gin Leu Ser Leu Leu Thr Leu Val Leu Leu Ser Pro Val 1 5 10 15 Ser Ala Asp Asn Phe Tyr Gin Asp Ala Ala Val Thr Phe Gly Asp Gin 20 25 30 Arg Ala Gin He Gin Asp Gly Gly Arg Leu Leu Thr Leu Ser Leu Asp 35 40 45 Lys He Ser Gly Ser Gly Phe Gin Ser Lys Asn Glu Tyr Leu Phe Gly 50 55 60 Arg Phe Asp Met Gin Leu Lys Leu Val Pro Gly Asn Ser Ala Gly Thr 65 70 75 80 Val Thr Thr Phe Tyr Leu Ser Ser Gin Gly Ala Gly His Asp Glu He 85 90 95 Asp Phe Glu Phe Leu Gly Asn Ser Ser Gly Leu Pro Tyr Thr Val His 100 105 110 Thr Asn Val Tyr Ser Gin Gly Lys Gly Asn Lys Glu Gin Gin Phe Arg 115 120 125 Leu Trp Phe Asp Pro Thr Ser Ser Phe His Thr Tyr Ser He Val Trp 130 135 140 Asn Ser Gin Arg He He Phe Leu Val Asp Asn He Pro He Arg Val 145 150 155 160 Phe Asn Asn His Glu Ala Leu Gly Val Ala Tyr Pro Lys Asn Gin Ala 165 170 175 Met Arg Val Tyr Ala Ser Leu Trp Asn Ala Asp Asp Trp Ala Thr Gin 180 185 190 Gly Gly Arg Val Lys Thr Asp Trp Ser Met Ala Pro Phe Thr Ala Ser 195 200 205 Tyr Arg Asn Phe Asn Thr Asn Ala Cys Val Trp Ser Ala Ala Thr Ser 210 215 220 Thr Ser Ser Cys Gly Gly Ser Lys Thr Glu Ser Val Asn Asn Asp Glu 225 230 235 240 Thr Trp Gin Thr Gin Gin Leu Asn Ala Asn Gly Arg Asn Arg He Arg 245 250 255 Trp Val Gin Gin Lys Tyr Met He Tyr Asn Tyr Cys Ala Asp Ala Asn 260 265 270 Arg Phe Ser Gin Gly Phe Ser Pro Glu Cys Lys Arg Ser Arg Phe 275 280 285 (2) INFORMATION FOR SEQ ID NO: 9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iii) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9: AAGCπCCTC AACATCAAAG GGTAGA 26 (2) INFORMATION FOR SEQ ID NO: 10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iii) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10: AAGCπCATG ATGAAATCGA TAπGA 26 (2) INFORMATION FOR SEQ ID NO: 11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iii) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11: GGATCCTCAA TATCGAπTC ATCATG 26 (2) INFORMATION FOR SEQ ID NO: 12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iii) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12: AAGCπCAπ TATGGTπGA TCCAAC 26 (2) INFORMATION FOR SEQ ID NO: 13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iii) ANTI -SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13: GGATCCGπG GATCAAACCA TAAATG 26 (2) INFORMATION FOR SEQ ID NO: 14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iii) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14: GGATCCGπA ACGTGTGGTC TCGTGT 26 (2) INFORMATION FOR SEQ ID NO: 15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iii) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15: GAYGARATNG AYWTHGARπ 20 (2) INFORMATION FOR SEQ ID NO: 16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iii) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16: GTNGGRTCRA ACCANARRTG 20 (2) INFORMATION FOR SEQ ID NO: 17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iii) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17: CGATGCAGCT GGAAHTCA 19 (2) INFORMATION FOR SEQ ID NO: 18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iii) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18: AGTTTGAGCT GCATATCGAA 20 (2) INFORMATION FOR SEQ ID NO: 19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (i i ) MOLECULE TYPE : cDNA ( i i i ) HYPOTHETICAL : NO (i i i ) ANTI -SENSE : NO (xi ) SEQUENCE DESCRIPTION : SEQ ID NO: 19 : πTGATCCCA CCTCGCCGπ 20 (2) INFORMATION FOR SEQ ID NO : 20 : ( i ) SEQUENCE CHARACTERISTICS : (A) LENGTH : 20 base pai rs (B) TYPE : nucl ei c aci d (C) STRANDEDNESS : si ngl e (D) TOPOLOGY : l i near (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iii) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20: CAGCTGACCA AACACAAGCA 20 (2) INFORMATION FOR SEQ ID NO: 21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iii) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21: AπAACCCTC ACTAAAGGGA 20 (2) INFORMATION FOR SEQ ID NO: 22: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iii) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22: TAATACGACT CACTATAGGG 20 (2) INFORMATION FOR SEQ ID NO: 23: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iii) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23: GππCCCAG TCACGACGT 19 (2) INFORMATION FOR SEQ ID NO: 24: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iii) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24: AATATCAGCG GAAACAGGG 19 (2) INFORMATION FOR SEQ ID NO: 25: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iii) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25: CCCTGπTCC GCTGATAAπ 20 (2) INFORMATION FOR SEQ ID NO: 26 : ( i ) SEQUENCE CHARACTERISTICS : (A) LENGTH : 20 base pai rs (B) TYPE: nucleic acid (C) STRANDEDNESS : si ngl e (D) TOPOLOGY : l i near (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iii) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26: CTAπAGCAT CTGCACAGTA 20 (2) INFORMATION FOR SEQ ID NO: 27: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iii) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27: TACTGTGCAG ATGCTAATAG 20 (2) INFORMATION FOR SEQ ID NO: 28: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iii) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28: GGAGGACGGG TGAAGACAGA 20 (2) INFORMATION FOR SEQ ID NO: 29: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iii) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29: GTGTAAGGTA GTCCTGATGA 20 (2) INFORMATION FOR SEQ ID NO: 30: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iii) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30: TCATCAGGAC TACCπACAC ' 20 (2) INFORMATION FOR SEQ ID NO: 31: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iii) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31: CCCπGGATC CGCTATAAπ 20 (2) INFORMATION FOR SEQ ID NO: 32: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 amino acids (B) TYPE: amino acid (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO (iii) ANTI-SENSE: NO (v) FRAGMENT TYPE: N-terminal (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32: Met Arg Gly Ser His His His His His His Gly Ser Ala Asp Asn Phe 1 5 10 15 Tyr Gin Asp Ala 20 (2) INFORMATION FOR SEQ ID NO: 33: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 15 amino acids (B) TYPE: amino acid (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO (iii) ANTI-SENSE: NO (v) FRAGMENT TYPE: N-terminal (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33: Gly Tyr Pro Arg Arg Pro Val Asp Val Pro Phe Trp Lys Asn Tyr 1 5 10 15 (2) INFORMATION FOR SEQ ID NO: 34: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iii) ANTI -SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34: ATCGGGAGCG GCGATACCGT A 21

Claims: Claims 1. A polypeptide having xyloglucan endo-transglycosylase (XET) activity, comprising substantially residues 21-289 of the amino acid sequence shown in Figure 1 (Seq ID No. 2) or functional equivalents thereof. 2. A polypeptide according to claim 1, comprising substantially residues 1-289 of the amino acid sequence shown in Figure 1. 3. A polypeptide according to claim 1, comprising substantially residues 19-287 of the amino acid sequence shown in Figure 5 (Seq ID No. 8). 4. A polypeptide according to claim 1, comprising substantially residues 1-287 of the amino acid sequence shown in Figure 1. 5. A polypeptide according to any one of the preceding claims, having at least 80% homology with the sequence of residues 21-289 of the sequence shown in Figure 1. 6. A polypeptide according to any one of the preceding claims, having at least 85% homology with the sequence of residues 21-289 of the sequence shown in Figure 1. 7. A polypeptide according to any one of the preceding claims, having at least 90% homology with the sequence of residues 21-289 of the sequence shown in Figure 1. 8. A polypeptide according to any one of the preceding claims comprising one or more of the following pep tides (possibly with up to one, or at most two, amino acid differences in each peptide): DEIDFEFLGN; SLWNADDWAT; FYSKNEYLFG; and GTVTTFYLSS 9. A polypeptide in accordance with any one of the preceding claims, substantially in isolation from other plant-derived substances. 10. A nucleotide sequence encoding subtantially the amino acid sequence of residues 21- 289 of the amino acid sequence shown in Figure 1, or functional equivalents thereof. 11. A nucleotide sequence according to claim 10, comprising substantially the DNA sequence shown in Figure 1 (Seq ID No. 1). 12. A nucleotide sequence according to claim 10, encoding substantially the amino acid sequence of residues 19-287 of the amino acid sequence shown in Figure 5. 13. A nucleotide sequence according to claim 12 comprising substantially the DNA sequence shown in Figure 5 (Seq ID No. 7). 14. A nucleotide sequence according to claim 10 or 12, further comprising a promoter to enable expression in a host cell. 15. A sequence according to claim 14, wherein the promoter is not one with which the sequence is naturally associated in a plant. 16. A nucleotide sequence according to claim 10. having at least 70% homology with the nucleotide sequence of Figure 1. 17. A nucleotide sequence according to claim 16, having at least 80% homology with the nucleotide sequence of Figure 1. 18. A nucleotide sequence according to claim 16, having at least 85% homology with the nucleotide sequence of Figure 1. 19. A nucleotide sequence according to any one of claims 10-18, encoding a polypeptide in accordance with any one of claims 1-9. 20. A nucleotide sequence according to claim 10, being an antisense functional equivalent having at least 70% homology with the complement of the nucleotide sequence of Figure 1. 21. A nucleotide sequence according to claim 20, having at least 80% homology with the complement of the nucleotide sequence of Figure 1. 22. A nucleotide sequence according to claim 20, having at least 90% homology with the complement of the nucleotide sequence of Figure 1. 23. A DNA vector comprising a sequence in accordance with any one of claims 10-22. 24. A vector according to claim 23 capable, when introduced into a suitable host, of directing the expression of a polypeptide according to any one of claims 1-9. 25. A host cell into which has been introduced a nucleotide sequence in accordance with any one of claims 10-22, or the progeny thereof. 26. A host cell according to claim 25, comprising a vector in accordance with claim 23 or 24. 27. A method of making a polypeptide having xyloglucan endo-transglycosylase (XET) activity, comprising the steps of: introducing a vector in accordance with claim 24 into a suitable host cell; growing the host cell and/ or the progeny thereof in suitable culture conditions such that the polypeptide is expressed; and obtaining the polypeptide from the culture medium and/ or the host cells. 28. A method according to claim 27, wherein the host cell is a plant cell or a micro¬ organism. 29. A method according to claim 27 or 28, wherein the host cell is a yeast cell. 30. A method of altering the characteristics of a plant or part thereof, comprising introducing into the plant or part thereof an effective portion of a nucleotide sequence in accordance with any one of claims 10-22, so as to alter the level of XET activity in the plant or part thereof. 31. A method according to claim 30, wherein the level of XET activity in the plant or part thereof is reduced. 32. A method according to claim 30 or 31, wherein one or more of the following characteristics are altered: size, rate of growth, texture, ripening. 33. A genetically engineered plant made by the method of claim 30, 31 or 32, or the progeny of such a plant.

Inventors: ARROWSMITH DAVID ANDREW, DE SILVA JACQUELINE, HELLYER SUSAN AMANDA, WHITEMAN SALLY-ANNE, ARROWSMITH, DAVID, ANDREW, DE SILVA, JACQUELINE, HELLYER, SUSAN, AMANDA, WHITEMAN, SALLY-ANNE
Applicants: ARROWSMITH DAVID ANDREW, HELLYER SUSAN AMANDA, SILVA JACQUELINE DE, UNILEVER NV, UNILEVER PLC, WHITEMAN SALLY ANNE, ARROWSMITH, DAVID, ANDREW, DE SILVA, JACQUELINE, HELLYER, SUSAN, AMANDA, UNILEVER N.V., WHITEMAN, SALLY-ANNE
Application year: 1994
Main classification: C12N15
IPC codes: A01H5, C07K7, C07K14, C12N1, C12N5, C12N9, C12N15, C12P21